BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 24236715)

  • 1. Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.
    Thaler F
    Pharm Pat Anal; 2012 Mar; 1(1):75-90. PubMed ID: 24236715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.
    Giannini G; Cabri W; Fattorusso C; Rodriquez M
    Future Med Chem; 2012 Jul; 4(11):1439-60. PubMed ID: 22857533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors: novel agents in cancer treatment.
    Glass E; Viale PH
    Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.
    Thaler F; Mercurio C
    ChemMedChem; 2014 Mar; 9(3):523-6. PubMed ID: 24730063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vorinostat.
    Grant S; Easley C; Kirkpatrick P
    Nat Rev Drug Discov; 2007 Jan; 6(1):21-2. PubMed ID: 17269160
    [No Abstract]   [Full Text] [Related]  

  • 6. Histone deacetylase inhibitors: a review on class-I specific inhibition.
    Behera J; Jayaprakash V; Sinha BN
    Mini Rev Med Chem; 2015; 15(9):731-50. PubMed ID: 25994050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecule of the month. Vorinostat.
    Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
    [No Abstract]   [Full Text] [Related]  

  • 8. Histone deacetylase inhibitors in cancer therapy.
    Fouladi M
    Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
    [No Abstract]   [Full Text] [Related]  

  • 9. Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.
    Med Lett Drugs Ther; 2007 Mar; 49(1256):23-4. PubMed ID: 17351559
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
    Hymes KB
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):98-109. PubMed ID: 20371442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorinostat approved for rare lymphoma.
    Thompson CA
    Am J Health Syst Pharm; 2006 Nov; 63(22):2168. PubMed ID: 17090730
    [No Abstract]   [Full Text] [Related]  

  • 12. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Duvic M; Dimopoulos M
    Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors in the treatment of lymphoma.
    Lemoine M; Younes A
    Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma.
    VanderMolen KM; McCulloch W; Pearce CJ; Oberlies NH
    J Antibiot (Tokyo); 2011 Aug; 64(8):525-31. PubMed ID: 21587264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.
    Khan O; La Thangue NB
    Immunol Cell Biol; 2012 Jan; 90(1):85-94. PubMed ID: 22124371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romidepsin: a novel histone deacetylase inhibitor for cancer.
    Bertino EM; Otterson GA
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
    Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
    Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
    Jazirehi AR
    Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
    Slingerland M; Guchelaar HJ; Gelderblom H
    Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
    Rangwala S; Zhang C; Duvic M
    Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.